Riina Kandolin

Riina Kandolin

Auto-generated profile, based on publicly available information

Riina Kandolin

Helsinki University Hospital , Haartmaninkatu 4, 00290 Helsinki

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2019 in European Heart Journal
Verified
Journal Article
Closed access
KEKaj Ekström
Kaj Ekström
JLJukka Lehtonen
Jukka Lehtonen
HNHanna-Kaisa Nordenswan
Hanna-Kaisa Nordenswan
MMMikko I Mäyränpää
Mikko I Mäyränpää
Anne Räisänen-SokolowskiAnne Räisänen-Sokolowski
Anne Räisänen-Sokolowski
MKMarkku Kupari
Markku Kupari
Aims: The present study was done to assess the role of sudden cardiac death (SCD) among the presenting manifestations of and fatalities from cardiac sarcoidosis (CS).Methods and results: We analysed altogether 351 cases of CS presenting from year 1998 through 2015 in Finland. There were 262 patients with a clinical diagnosis and treatment of CS, 27 patients with an initial lifetime diagnosis of giant cell myocarditis that was later converted to CS, and 62 cases detected at autopsy and identified by screening >820 000 death certificates from the national cause-of-death registry. The total case series comprised 253 females and 98 males aged on average 52 years at presentation. High-grade atrioventricular block was the most common first sign of CS (n = 147, 42%) followed by heart failure (n = 58, 17%), unexpected fatal (n = 38) or aborted (n = 12) SCD (14%), and sustained ventricular tachycardia (n = 48, 14%). Severe coronary artery disease was found at autopsy concomitant with CS in four of the 38 cases presenting with fatal SCD. Of all deaths recorded till the end of 2015, 64% (n = 54/84) were unexpected SCDs from CS that had either been silent during life or defied all attempts at diagnosis. The Kaplan–Meier estimate (95% CI) of survival from symptom onset was 85% (80–90%) at 5 years and 76% (68–84%) at 10 years.Conclusion: Together fatal and aborted SCD constitute 14% of the presenting manifestations of CS. Nearly two-thirds of all fatalities from CS are caused by undiagnosed granulomas in the heart.

1 May 2019 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
RKRiina Kandolin
Riina Kandolin
KEKaj Ekström
Kaj Ekström
TSTrevor Simard
Trevor Simard
BHBenjamin Hibbert
Benjamin Hibbert
PNPablo Nery
Pablo Nery
DBDavid Birnie
David Birnie
Cardiac sarcoidosis (CS) is increasingly recognized as a cause of diverse cardiac manifestations. Spontaneous coronary artery dissection (SCAD) has emerged as an important cause of acute coronary syndrome especially among young females. The prevalence of sarcoidosis in the causal spectrum of SCAD has not been described before but sarcoidosis is cited as a potential yet rare cause of SCAD. We aimed to examine the frequency and characteristics of SCAD in CS. Searching two prospective CS registries with 481 CS patients, we found only one case of manifest SCAD. She is a 61-year-old female previously diagnosed with endomyocardial biopsy confirmed CS. She presented with chest pain and elevated troponin. Coronary angiogram revealed two-vessel SCAD. Fluorodeoxyglucose positron emission tomography scan showed likely reactivation of CS. The patient was treated with dual antiplatelet therapy and immunosuppression. Repeat angiogram showed complete resolution of the coronary lesions.

7 July 2020 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
PDF file
CWChristiane Wiefels
Christiane Wiefels
OLOlabimpe Lamai
Olabimpe Lamai
RKRiina Kandolin
Riina Kandolin
DBDavid Birnie
David Birnie
ELEugene Leung
Eugene Leung
RBRob Beanlands
Rob Beanlands


25 February 2026 in ESC Heart Failure
Verified
Journal Article
Open access
RKRiina Kandolin
Riina Kandolin
SPSami Pakarinen
Sami Pakarinen
PKPaavo Koivistoinen
Paavo Koivistoinen
STSaara Tiainen
Saara Tiainen
JKJan Kiss
Jan Kiss
MPMarkku Pentikäinen
Markku Pentikäinen
Aims: This real-world, retrospective study aimed to evaluate clinical outcomes and healthcare costs in advanced heart failure (HF) patients treated at Helsinki University Hospital with heart transplantation (HTx) or elective or urgent left ventricular assist device (LVAD) therapy over 3 years. Methods and results: Data were extracted from electronic medical records and validated through clinician review. Patients (n = 78) were categorized into three groups: Group 1, HTx as first procedure, stratified into those without (1a, n = 25) and with (1b, n = 11) prior LVAD; Group 2, elective LVAD (n = 30); and Group 3, urgent LVAD (n = 12). Study endpoints included survival, 6-minute walk test (6MWT) results, and healthcare costs at 3, 6, 12, and 24 months. Outcomes and costs were indirectly compared to explore their implications for future patient selection strategies. Survival exceeded 80% in groups 1 and 2. Group 1a had a 24-month survival rate of 84.0% (95% CI: 0.628–0.937), with most deaths (3 of 4) occurring within the first 3 months. Group 1b showed 100% survival throughout follow-up, and group 2 stabilized at 93.4% (95% CI: 0.759–0.983) after two early deaths. Group 3 had a progressive decline to 62.5% at 24 months (95% CI: 0.268–0.846). The confidence intervals between these groups overlap due to the small sample size in group 3. Observed 6-minute walking test (6MWT) performance improved steadily over the first year in all groups, with increases in distance walked and percentage of predicted values observed increasing between baseline and 12 months. Most healthcare expenses were concentrated within the first 3 months post-surgery. At 3 months, median costs per patient were €177 380 [IQR €121 900] (1a), €207 826 [IQR €83 398] (1b), €187 558 [IQR €67 664] (2), and €293 355 [IQR €67 664] (3). Group 3 incurred significantly higher costs compared to groups 1a (P = .004) and 2 (P = .003). While no significant difference was observed between group 3 and group 1b (P = .335), a difference was observed when group 1a and b were pooled. These trends were consistent at 6 months. The differences were no longer statistically significant at 12 and 24 months, which may be due to wider cost variation or diminishing sample size. Conclusion: Elective LVAD in patients with advanced HF offers survival outcomes comparable to HTx and incurs similar costs and is preferable to urgent LVAD, which is associated with higher costs and may lead to poorer outcomes. These findings support more proactive patient selection and care pathway optimization in advanced HF.